Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats

Bone

Volumn 37, Issue 1, 2005, Pages 87-95

  Valenta, A ^a,b   Roschger, P ^a   Fratzl Zelman, N ^a   Kostenuik, P J ^c   Dunstan, C R ^c   Fratzl, P ^d   Klaushofer, K ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF LEOBEN   (Austria)

^c AMGEN INC   (United States)

^d MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES   (Germany)

Author keywords

Aged OVX rats; Bone material; OPG and PTH; qBEI; SAXS

Indexed keywords

OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34];

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE STRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMUR; INTERMETHOD COMPARISON; METAPHYSIS; NONHUMAN; OVARIECTOMY; PARAMETER; QUANTITATIVE ANALYSIS; RAT; STATISTICAL SIGNIFICANCE; THICKNESS; TIME SERIES ANALYSIS; TRABECULAR BONE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; CALCIUM; DRUG THERAPY, COMBINATION; ELECTRON PROBE MICROANALYSIS; FEMUR; GLYCOPROTEINS; HUMANS; MINERALS; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TERIPARATIDE;

EID: 20544468667     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.03.013     Document Type: Article

References (48)

1. G.A. Rodan, L.G. Raisz, and J.P. Bilezikian Pathophysiolgy of osteoporosis J.P. Bilezikian L.G. Raisz G.A. Rodan 2nd ed. Principles of bone biology vol. 2 2002 Academic Press New York 1275 1289
2. F.J. Lopez New approaches to the treatment of osteoporosis Curr. Opin. Chem. Biol. 4 2000 383 393
3. G.A. Rodan, and T.J. Martin Therapeutic approaches to bone diseases Science 289 2000 1508 1514
4. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, and R. Elliott Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
5. P.J. Kostenuik, and V. Shalhoub Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption Curr. Pharm. Des. 7 2001 613 635
6. P.J. Kostenuik, C. Capparelli, S. Morony, S. Adamu, G. Shimamoto, and V. Shen OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats Endocrinology 142 2001 4295 4304
7. J. Reeve, P.J. Meunier, J.A. Parsons, M. Bernat, O.L.M. Bijvoet, and P. Courpron Anabolic effect of human parathyroid-hormone fragment on trabecular bone in involutional osteoporosis-A multicenter trial Br. Med. J. 280 1980 1340 1344
8. H. Dobnig, and R.T. Turner Evidence that intermittent treatment with parathyroid-hormone increases bone-formation in adult-rats by activation of bone lining cells Endocrinology 136 1995 3632 3638
9. L.J. Gibson, and M.F. Ashby Cellular solids, structure and properties 1999 Cambridge University Press Cambridge
10. A. Woesz, J. Stampfl, and P. Fratzl Cellular solids beyond the apparent density-An experimental assessment of mechanical properties Adv. Eng. Mater. 6 2004 134 138
11. W.J. Landis The strength of a calcified tissue depends in part on the molecular-structure and organization of its constituent mineral crystals in their organic matrix Bone 16 1995 533 544
12. P. Fratzl, H.S. Gupta, E.P. Paschalis, and P. Roschger Structure and mechanical quality of the collagen-mineral nano-composite in bone J. Mater. Chem. 14 2004 2115 2123
13. E. Samnegard, U.T. Iwaniec, D.M. Cullen, D.B. Kimmel, and R.R. Recker Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats Bone 28 2001 251 260
14. D.W. Dempster, F. Cosman, E.S. Kurland, H. Zhou, J. Nieves, and L. Woelfert Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study J. Bone Miner. Res. 16 2001 1846 1853
15. A.B. Hodsman, and B.M. Steer Early histomorphometric changes in response to parathyroid-hormone therapy in osteoporosis-evidence for de novo bone-formation on quiescent cancellous surfaces Bone 14 1993 523 527
16. R.L. Jilka, R.S. Weinstein, T. Bellido, P. Roberson, A.M. Parfitt, and S.C. Manolagas Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone J. Clin. Invest. 104 1999 439 446
17. H. Dobnig, and R.T. Turner The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats Endocrinology 138 1997 4607 4612
18. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, and J.Y. Reginster Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 344 2001 1434 1441
19. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, and T.F. Lang The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N. Engl. J. Med. 349 2003 1207 1215
20. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, and R.M. Neer The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N. Engl. J. Med. 349 2003 1216 1226
21. P.D. Delmas, P. Vergnaud, M.E. Arlot, P. Pastoureau, P.J. Meunier, and M.H. Nilssen The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16 1995 603 610
22. J. Li, I. Sarosi, X.Q. Yan, S. Morony, C. Capparelli, and H.L. Tan RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proc. Natl. Acad. Sci. U. S. A. 97 2000 1566 1571
23. J.C. Huang, T. Sakata, L.L. Pfleger, M. Bencsik, B.P. Halloran, and D.D. Bikle PTH differentially regulates expression of RANKL and OPG J. Bone Miner. Res. 19 2004 235 244
24. S. Khosla Minireview: the OPG/RANKL/RANK system Endocrinology 142 2001 5050 5055
25. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, and R. Luthy Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
26. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, and C. Capparelli OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
27. K. Redlich, B. Gortz, S. Hayer, J. Zwerina, N. Doerr, and P. Kostenuik Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis Am. J. Pathol. 164 2004 543 555
28. B.M. Misof, P. Roschger, F. Cosman, E.S. Kurland, W. Tesch, and P. Messmer Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J. Clin. Endocrinol. Metab. 88 2003 1150 1156
29. P. Fratzl, S. Schreiber, P. Roschger, M.H. Lafage, G. Rodan, and K. Klaushofer Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle X-ray scattering and backscattered electron imaging study J. Bone Miner. Res. 11 1996 248 253
30. P. Roschger, S. Rinnerthaler, J. Yates, G.A. Rodan, P. Fratzl, and K. Klaushofer Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Bone 29 2001 185 191
31. P. Roschger, P. Fratzl, K. Klaushofer, and G. Rodan Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs Bone 20 1997 393 397
32. A. Boyde, E. Maconnachie, S.A. Reid, G. Delling, and G.R. Mundy Scanning electron-microscopy in bone pathology-review of methods, potential and applications Scanning Electron. Microsc. 1986 1986 1537 1554
33. R.D. Bloebaum, J.G. Skedros, E.G. Vajda, K.N. Bachus, and B.R. Constantz Determining mineral content variations in bone using backscattered electron imaging Bone 20 1997 485 490
34. P. Roschger, H. Plenk, K. Klaushofer, and J. Eschberger A new scanning electron-microscopy approach to the quantification of bone-mineral distribution-backscattered electron image grey-levels correlated to calcium K-alpha-line intensities Scanning Microsc. 9 1995 75 88
35. P. Roschger, P. Fratzl, J. Eschberger, and K. Klaushofer Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies Bone 23 1998 319 326
36. P. Fratzl, M. Groschner, G. Vogl, H. Plenk, J. Eschberger, and N. Fratzl-Zelman Mineral crystals in calcified tissues-A comparative-study by Saxs J. Bone Miner. Res. 7 1992 329 334
37. P. Fratzl, S. Schreiber, and K. Klaushofer Bone mineralization as studied by small-angle X-ray scattering Connect. Tissue Res. 35 1996 9 16
38. S. Rinnerthaler, P. Roschger, H.F. Jakob, A. Nader, K. Klaushofer, and P. Fratzl Scanning small angle X-ray scattering analysis of human bone sections Calcif. Tissue Int. 64 1999 422 429
39. M. Gunness-Hey, and J.M. Hock Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone Metab. Bone Dis. Res. 5 1984 177 181
40. P. Fratzl, P. Roschger, J. Eschberger, B. Abendroth, and K. Klaushofer Abnormal bone mineralization after fluoride treatment in osteoporosis-A small-angle X-ray-scattering study J. Bone Miner. Res. 9 1994 1541 1549
41. O. Paris, I. Zizak, H. Lichtenegger, P. Roschger, K. Klaushofer, and P. Fratzl Analysis of the hierarchical structure of biological tissues by scanning X-ray scattering using a micro-beam Cell. Mol. Biol. 46 2000 993 1004
42. E. Samnegard, M.P. Akhter, and R.R. Recker Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats Bone 28 2001 414 422
43. M. Kneissel, A. Boyde, and J.A. Gasser Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34) Bone 28 2001 237 250
44. R.T. Turner, G.L. Evans, J.M. Cavolina, B. Halloran, and E. Morey-Holton Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats Endocrinology 139 1998 4086 4091
45. C. Capparelli, S. Morony, K. Warmington, S. Adamu, D. Lacey, and C.R. Dunstan Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats J. Bone Miner. Res. 18 2003 852 858
46. P.J. Kostenuik, B. Bolon, S. Morony, M. Daris, Z.O. Geng, and C. Carter Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice Bone 34 2004 656 664
47. P. Fratzl, H.S. Gupta, E.P. Paschalis, and P. Roschger Structure and mechanical quality of the collagen-mineral nano-composite of bone J. Mater. Chem. 14 2004 2115 2123
48. W. Tesch, T. Vandenbos, P. Roschger, N. Fratzl-Zelman, K. Klaushofer, and W. Beertsen Orientation of mineral crystallites and mineral density during skeletal development in mice deficient in tissue nonspecific alkaline phosphatase J. Bone Miner. Res. 18 2003 117 125